Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to final results from a Southwest Oncology Group study, led by UC Davis Cancer Center researchers. In the study, patients taking bortezomib plus gemcitabine and carboplatin had a median survival of 11 months, compared to nine months in past SWOG trials, reported Angela Davies, an assistant professor of hematology and oncology at UC Davis Cancer Center and lead author of the study.